Article Information
History
- July 3, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Chrysovalantis Voutouria,b,
- C. Corey Hardinc,
- Vivek Naranbhaid,e,f,
- Mohammad R. Nikmaneshia,g,
- Melin J. Khandekarh,
- Justin F Gainord,
- Triantafyllos Stylianopoulosb,1,
- Lance L. Munna,1 and
- Rakesh K. Jaina,1
- aEdwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
- bCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering,University of Cyprus, Nicosia, Cyprus
- cDepartment of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA
- dMassachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA
- eDana-Farber Cancer Institute, Boston, MA
- fCenter for the AIDS Programme of Research in South Africa, Durban, South Africa
- gDepartment of Mechanical Engineering, Sharif University of Technology, Tehran, Iran
- hDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
- ↵1To whom correspondence may be addressed: T.S. tstylian{at}ucy.ac.cy, L.L.M. munn{at}steele.mgh.harvard.edu, and R.K.J. jain{at}steele.mgh.harvard.edu
Author Contributions: C.V., performed research, C.C.H., T.S., L.L.M., and R.K.J. designed research, C.C.H., V.N., M.N., M.J.K., J.F.G., T.S., L.L.M., and R.K.J supervised model development, all authors analyzed data and wrote the article.
Posted July 03, 2022.
Mechanistic model for booster doses effectiveness in healthy, cancer and immunosuppressed patients infected with SARS-CoV-2
